Not turning bullish after latest LS approval.
Aegis Capital affirms Navidea Biopharma (AMEX: NAVB) at Hold with a price target of $2 following FDA approval of Lymphoseek's NDA for the drug to be used in lymphatic mapping in solid tumors.
Analyst Ram Selvaraju commented, While this is a significant regulatory milestone for the company and could permit Navidea to access a market of up to 1.2mm solid tumor patients, we remain neutral pending further demonstration of Lymphoseek commercial traction, to the point at which the product's revenues begin to exceed our expectations.
Our valuation methodology provides for a contribution of only $1.30 per share in value from Lymphoseek. Therefore while we believe that there is room for upside from the current share price, we feel that the risk/reward profile of the firm at this stage needs to improve before we can be more bullish on the name. The pipeline also needs to progress before we can have greater confidence in its value.
Trader who posts his picks on iHub. Google "ihub $heffs-$tation" and it should come up. You'll get a kick out of the circa 1997 spinning/blinking animations.
Of course he was shown the door. After listening to some of his presentations, the last one where he sarcastically asked if anyone cared to leave a resume for his job, he deserved to go.
Google "Chembio Diagnostics Enters the Fray" for complete article.
Chembio Diagnostics, as the name suggests, makes rapid-response diagnostic tests. Its focus is on syphilis and HIV, but whispers have been floating around that it's working on a rapid-response Ebola test for use in the field and/or in emergency rooms where speed of treatment is crucial.
I listened to the Oct. 7 presentation. In three days they went from, "approximately two years" to "at least the next 12 months." Great.
Pump and dump shop.
He put out his alert, and here we are at .28. Note: I removed all his links so it would post here.
$heff Member Level Friday, 10/03/14 09:59:16 AM
Re: $heff post# 83387
Post # of 83406
Beginner Portfolio Update..bought a starter in a stock that should do well in the 4th quarter. Company is expecting to hear from the FDA regarding an ADCOM meeting in 2015. This is a fully-reporting OTCBB stock that has several pending catalysts left in 2014/early 2015.
Alert..bought starter in GTHP in the Beginner Portfolio at $.285. This company should do well with increased attention being given to it in Q4.
Rodman Renshaw 9/11/14 Presentation
$GTHP insider buying
$GTHP….has a market cap of 20m. They had only 1m in cash as they go into a potential ADCOM for their LuViva for cervical Cancer.
GTHP has 55m shares in the float and 78m shares outstanding. 71,000 share avg past 3 months. 37,000 volume past 10 days. The 52wk low is $.24 and the 52wk high is $.75.
GTHP-S1 On Sept 12th…
Not exactly a buy, but he did mention it. This guy has enough followers to impact price/volume for about 10 minutes. I think people give him way too much credit.
$heff Member Level Thursday, 10/02/14 03:35:37 PM
Re: bigcat2 post# 75684
Post # of 83390
$GTHP...watching this one closely here. This is a fully-reporting OTCBB that I will add to my list of four here shortly. The stock has pending catalysts in Q4 of this year and Q1 of 2015. On high alert here!
Ugh, .275 today. You're right, GC killed the share price with the .307 shares on a very small deal. Coming from big companies, I doubt he ever had to raise capital. I think he'll be lucky to get a deal at .25 at this point.
It came in on Schwab news feed at 4:02, links to the same signup form. Another bear raid...more .95 shares tomorrow? Amazing.
"this would have been approved by the FDA long ago if the ducks were truly in a row." I didn't used to think that way but began to wonder if there were problems after seeing the last presentation where GC noted that GTHP had answered more than 100 questions from the FDA. That seems like an awful lot of questions; I can't recall any other company I've owned putting a number on FDA questions. I've made my bet (75,000 shares) and will let it ride but won't be adding any more. Good luck, everyone.
We're approaching a five-year low...looking like we may have another week of new 52-week lows. Not fun to watch.
"Watch the shares make a new low." I think that's a given. Yes, that is my smart-a@@ bid at .2701.
Almost a 20% discount from Friday's close and the stock has to triple the issue price and stay there for 30 days to get another $300,000. If GTHP is going to sell shares at .3072 to raise only $200,000 it is a little scary to think what the share price would be for any meaningful size investment. Apparently they're not finding a lot of willingness to invest in them without having FDA approval. Again, an FDA play.
The selling in the .30s hasn't been fun to watch but I'll admit I added a little more this week. GC still has a lot more riding on GTHP than I do though... Happy hour awaits. Good luck.
Why don't you call Levi & Korsinsky? Then let everyone know what they've unearthed. "Could take years to resolve." LOL. You took the biggest dump in the bed of stupidity that I've seen in a long time. Have a nice day.